In 2024, Jiangsu Hengrui Pharmaceuticals achieved record high revenue and net profit, with explosive growth in Innovative Drugs and research and development investment accounting for nearly 30% of revenue | Earnings Reports insights.
Net income is 6.337 billion yuan, a sharp increase of 47.28% year-on-year. Innovative Drugs sales reached 13.892 billion yuan, a year-on-year growth of 30.60%, accounting for nearly 50% of total revenue, becoming the core engine for performance growth.
Domestic Innovative Drugs are once again surging towards overseas markets! Concept stocks have responded with a significant increase. Is the external authorization model the optimal choice?
① As of the time of publication, the Hang Seng Innovative Drugs Index has risen over 5%, with multiple Innovative Drugs concept stocks experiencing double-digit gains; ② In recent days, Jiangsu Hengrui Pharmaceuticals, Hepo Pharmaceutical, UNITED LAB, and other Biotech companies have issued announcements about "going abroad"; ③ Northeast Securities stated that top MNCs recognize the R&D capabilities of Chinese local companies and are more willing to assign high valuations.
Sunshine Guojian Pharmaceutical (688336): The 2024 Earnings Reports show a revenue growth of 17.70% and a significant increase in Net income of 139.15%.
Sunshine Guojian Pharmaceutical 2024 Earnings Reports: Summary of significant performance growth driven by innovation and future challenges: Financial performance: In 2024, revenue is 1...
Merck And Jiangsu Hengrui Pharmaceuticals Entered Into An Exclusive License Agreement For HRS-5346, An Investigational Oral Small Molecule Lipoprotein(a) Inhibitor Currently In A Phase 2 Trial In China, Hengrui Pharma Will Receive An Upfront Payment...
Last year's loss narrowed mainly due to cutting R&D? Staidson's performance remains under pressure | Interpretations
① In 2024, Staidson's total revenue has declined again, and the loss continues, with the company having incurred losses for five consecutive years so far. ② During the reporting period, the company's R&D investment was 0.162 billion yuan, a decrease of 63.77% compared to the same period last year, with most major R&D projects in early clinical trial stages.
The FDA has once again delayed the approval for Jiangsu Hengrui Pharmaceuticals' PD-1 combination product.
Once again, it is a production compliance issue.